連環(huán)蛋白β1(β-catenin)重組蛋白
Recombinant Beta Catenin (β-catenin)
CTNNb1; bCat; b-Cat; CTNN-B1; Catenin Beta 1; Cadherin-Associated Protein
- 編號RPB021Hu02
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位細胞膜, 細胞核, 細胞質(zhì)
- 預(yù)測分子量79.1kDa
- 實際分子量79kDa(差異分析請參閱說明書)
- 片段與標簽Ala2~Val451 with N-terminal His and GST Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 80%
- 等電點5.9
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1032 ¥ 2580 ¥ 5160 ¥ 15480 ¥ 38700
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
SDS-PAGE圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB021Hu01 | 連環(huán)蛋白β1(β-catenin)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB021Hu02 | 連環(huán)蛋白β1(β-catenin)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB021Hu01 | 連環(huán)蛋白β1(β-catenin)多克隆抗體 | WB; IHC; ICC; IP. |
| CAB021Hu01 | 抗連環(huán)蛋白β1(β-catenin)多克隆抗體 | Loading Control of WB. |
| MAB021Hu23 | 連環(huán)蛋白β1(β-catenin)單克隆抗體 | WB; IHC; ICC; IP. |
| MAB021Hu24 | 連環(huán)蛋白β1(β-catenin)單克隆抗體 | WB; IHC; ICC; IP. |
| MAB021Hu25 | 連環(huán)蛋白β1(β-catenin)單克隆抗體 | WB; IHC; ICC; IP. |
| MAB021Hu27 | 連環(huán)蛋白β1(β-catenin)單克隆抗體 | WB; IHC; ICC; IP. |
| MAB021Hu21 | 連環(huán)蛋白β1(β-catenin)單克隆抗體 | WB; IHC; ICC; IP. |
| MAB021Hu22 | 連環(huán)蛋白β1(β-catenin)單克隆抗體 | WB; IHC; ICC; IP. |
| MAB021Hu26 | 連環(huán)蛋白β1(β-catenin)單克隆抗體 | WB; IHC; ICC; IP. |
| CAB021Hu22 | 抗連環(huán)蛋白β1(β-catenin)單克隆抗體 | Loading Control of WB |
| MAB021Hu29 | 連環(huán)蛋白β1(β-catenin)單克隆抗體 | WB; IHC; ICC; IP. |
| SEB021Hu | 連環(huán)蛋白β1(β-catenin)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB021Hu | 連環(huán)蛋白β1(β-catenin)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSB021Hu01 | 連環(huán)蛋白β1(β-catenin)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | 自己動手制作ELISA試劑盒的主要材料 |
參考文獻
| 雜志 | 參考文獻 |
| Clinica Chimica Acta | Versican and its associated molecules: Potential diagnostic markers for multiple myeloma [Pubmed:25623955] |
| Journal of Bone and Mineral Research | Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth [Pubmed:25639729] |
| Am J Transl Res | Role of SDF-1 and Wnt signaling pathway in the myocardial fibrosis of hypertensive rats [PubMed: 26396666] |
| Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA. [pubmed:28533512] |
| Life Sciences | Hepatoprotective effect of hesperidin in hepatocellular carcinoma: Involvement of Wnt signaling pathways. [pubmed:28754618] |
| Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA [Pubmed: 28533512] |
| The Showa University Journal of Medical Sciences | Eribulin Treatment Induces High Expression of miR-195 and Inactivates the Wnt/β-catenin Signaling Pathway in Triple-negative Breast Cancer [Doi: 10.15369/sujms.30.359] |
| Advances in?Medical?Sciences | Urinary procollagen III aminoterminal propeptide and β-catenin–New diagnostic biomarkers in solitary functioning kidney? [Pubmed: 30738287] |
| Biomed Pharmacother | Silence of FAM83H-AS1 promotes chemosensitivity of gastric cancer through Wnt/β-catenin signaling pathway [Pubmed: 32028241] |
| Journal of Cosmetic Dermatology | Novel complex of cosmetic ingredients with promising action in preventing hair loss and follicular aging through mechanism involving enrichment of WNT/signaling?… [Pubmed: 33179848] |
| Nutrients | Hydroxytyrosol as a Promising Ally in the Treatment of Fibromyalgia [Pubmed: 32784915] |
| Oncotarget | Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme [33473259] |
| Cytokine | QNZ alleviated hepatocellular carcinoma by targeting inflammatory pathways in a rat model [34564023] |
留言咨詢
